#ESMO26 | PANKU-Breast01

Phase III: iza-bren, an EGFR×HER3 bispecific ADC, vs chemotherapy in previously treated HR+/HER2− advanced BC (N=383).

▪️ mPFS: 8.2 vs 4.0 months
HR 0.41 (95% CI 0.33–0.53); P<0.0001
▪️ ORR: 40.5% vs 20.2%
▪️ OS immature
▪️ Grade ≥3 TRAEs predominantly hematologic; ILD 1.1% (grade 1–2)

Promising efficacy. Key question: where will it fit in ADC sequencing?

🔹 𝗕𝗠𝗦’𝘀 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗜𝗭𝗔𝗕𝗥𝗜𝗚𝗛𝗧-𝗕𝗿𝗲𝗮𝘀𝘁𝟬𝟭
𝘪𝘻𝘢-𝘣𝘳𝘦𝘯 𝘪𝘯 𝘢 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵 𝘱𝘰𝘱𝘶𝘭𝘢𝘵𝘪𝘰𝘯: 1𝘓 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘛𝘕𝘉𝘊 𝘰𝘳 𝘌𝘙-𝘭𝘰𝘸/𝘏𝘌𝘙2− 𝘉𝘊 𝘪𝘯𝘦𝘭𝘪𝘨𝘪𝘣𝘭𝘦 𝘧𝘰𝘳 𝘢𝘯𝘵𝘪–𝘗𝘋-(𝘓)1 𝘵𝘩𝘦𝘳𝘢𝘱𝘺.

#Breastcancer #ADCs #PANKUBreast01